🚀 VC round data is live in beta, check it out!
AstraZeneca Overview
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Founded
1992
HQ
Employees
94.3K
Website
Sectors
Financials (LTM)
EV
$341B
AstraZeneca Financials
AstraZeneca reported last 12-month revenue of $60B and EBITDA of $21B.
In the same LTM period, AstraZeneca generated $49B in gross profit, $21B in EBITDA, and $15B in net income.
Revenue (LTM)
AstraZeneca P&L
In the most recent fiscal year, AstraZeneca reported revenue of $59B and EBITDA of $20B.
AstraZeneca expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $60B | XXX | $59B | XXX | XXX | XXX |
| Gross Profit | $49B | XXX | $48B | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $21B | XXX | $20B | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $15B | XXX | $14B | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | — | — | $22B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AstraZeneca Stock Performance
AstraZeneca has current market cap of $317B, and enterprise value of $341B.
Market Cap Evolution
AstraZeneca's stock price is $204.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $341B | $317B | 0.0% | XXX | XXX | XXX | $9.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAstraZeneca Valuation Multiples
AstraZeneca trades at 5.7x EV/Revenue multiple, and 16.3x EV/EBITDA.
EV / Revenue (LTM)
AstraZeneca Financial Valuation Multiples
As of April 12, 2026, AstraZeneca has market cap of $317B and EV of $341B.
Equity research analysts estimate AstraZeneca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AstraZeneca has a P/E ratio of 21.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $317B | XXX | $317B | XXX | XXX | XXX |
| EV (current) | $341B | XXX | $341B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 16.9x | XXX | XXX | XXX |
| EV/EBIT | 17.7x | XXX | 18.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 21.5x | XXX | 22.2x | XXX | XXX | XXX |
| EV/FCF | 37.3x | XXX | 39.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AstraZeneca Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AstraZeneca Margins & Growth Rates
AstraZeneca's revenue in the last 12 month grew by 7%.
AstraZeneca's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
AstraZeneca's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AstraZeneca's rule of X is 56% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
AstraZeneca Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AstraZeneca Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
Valuation data powered by FactSet, Inc.
AstraZeneca M&A Activity
AstraZeneca acquired XXX companies to date.
Last acquisition by AstraZeneca was on XXXXXXXX, XXXXX. AstraZeneca acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AstraZeneca
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAstraZeneca Investment Activity
AstraZeneca invested in XXX companies to date.
AstraZeneca made its latest investment on XXXXXXXX, XXXXX. AstraZeneca invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AstraZeneca
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AstraZeneca
| When was AstraZeneca founded? | AstraZeneca was founded in 1992. |
| Where is AstraZeneca headquartered? | AstraZeneca is headquartered in United Kingdom. |
| How many employees does AstraZeneca have? | As of today, AstraZeneca has over 94K employees. |
| Is AstraZeneca publicly listed? | Yes, AstraZeneca is a public company listed on NYSE. |
| What is the stock symbol of AstraZeneca? | AstraZeneca trades under AZN ticker. |
| When did AstraZeneca go public? | AstraZeneca went public in 1993. |
| Who are competitors of AstraZeneca? | AstraZeneca main competitors are Roche, Merck, Novartis, AbbVie. |
| What is the current market cap of AstraZeneca? | AstraZeneca's current market cap is $317B. |
| What is the current revenue of AstraZeneca? | AstraZeneca's last 12 months revenue is $60B. |
| What is the current revenue growth of AstraZeneca? | AstraZeneca revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of AstraZeneca? | Current revenue multiple of AstraZeneca is 5.7x. |
| Is AstraZeneca profitable? | Yes, AstraZeneca is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AstraZeneca? | AstraZeneca's last 12 months EBITDA is $21B. |
| What is AstraZeneca's EBITDA margin? | AstraZeneca's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of AstraZeneca? | Current EBITDA multiple of AstraZeneca is 16.3x. |
| What is the current FCF of AstraZeneca? | AstraZeneca's last 12 months FCF is $9B. |
| What is AstraZeneca's FCF margin? | AstraZeneca's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of AstraZeneca? | Current FCF multiple of AstraZeneca is 37.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.